Skip to content
HowShorted

Keros Therapeutics, Inc. short interest in 2022

In 2022, Keros Therapeutics, Inc.'s disclosed short interest ran from 3.45% of shares outstanding on 14 Jan 2022 to 2.09% on 30 Dec 2022, a change of -1.36 percentage points. The year's high was 5.73% on 30 Jun 2022 and its low 2.09% on 15 Dec 2022, averaging 3.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.29 days on 15 Feb 2022. Full history: Keros Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Keros Therapeutics, Inc. in 2022

2022 in figures

Start of year
3.45% (14 Jan 2022)
End of year
2.09% (30 Dec 2022)
Change
-1.36 pp
High
5.73% (30 Jun 2022)
Low
2.09% (15 Dec 2022)
Average
3.57%
Highest days to cover
10.29 (15 Feb 2022)
SEC filings marked
8

Every report in 2022

Keros Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20223.45%7.51
31 Jan 20223.94%5.97
15 Feb 20224.50%10.29
28 Feb 20224.84%10.08
15 Mar 20224.81%10.0910-K filed, results (8-K)
31 Mar 20224.10%7.17
14 Apr 20223.61%5.65
29 Apr 20223.66%9.12
13 May 20224.12%5.4510-Q filed, results (8-K)
31 May 20223.85%3.65
15 Jun 20224.25%4.15
30 Jun 20225.73%3.95
15 Jul 20225.47%7.49
29 Jul 20223.96%4.49
15 Aug 20223.01%3.4110-Q filed, results (8-K)
31 Aug 20222.64%4.56
15 Sep 20222.72%3.53
30 Sep 20222.59%3.59
14 Oct 20222.93%1.90
31 Oct 20222.63%3.95
15 Nov 20222.58%3.1510-Q filed, results (8-K)
30 Nov 20222.16%3.58
15 Dec 20222.09%2.78
30 Dec 20222.09%3.75

See also: Keros Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.